Northern California Comprehensive Thalassemia Center


Standard of Care Guidelines 2012


Hematopoietic cell transplantation (HCT) is the only treatment that offers a potential cure for thalassemia at this time. HCT relies on high-dose chemotherapy to eliminate thalassemia-producing cells in the marrow and replaces them with healthy donor cells from bone marrow or umbilical cord blood, usually taken from a human-leukocyte antigen (HLA) match: an identical sibling. This therapy should be considered for all patients who have a suitable donor. Early referral to a transplant center is recommended, as HCT has a better outcome in younger patients.

Patients are classified before HCT as Class 1, 2 or 3 patients on the basis of risk factors that influence outcome after HCT. These risk factors include:

The overall thalassemia-free survival of low-risk, HLA-matched sibling stem cell transplantation patients is 85 to 90 percent, with a 95 percent overall survival. While not as effective, new approaches to Class 2 and 3 patients have significantly improved their overall survival. The problems of rejection and engraftment in these patients are improving with the use of more intensified immunosuppressive therapy.

If HCT is considered, patients should be referred to the nearest transplant center with experience in HCT for genetic diseases. The liver, lungs, heart, and skeleton are particular targets of complications of thalassemia and chronic transfusion. The following studies must be done before HCT:

  1. A staging of liver fibrosis and inflammatory lesions by liver biopsy, as per the Knodell numerical scoring system (Knodell, R.G., et al. Hepatology 1 [1981]: 431.), with measurement of LIC
  2. A measurement of hepatic, cardiac, endocrine, renal, and pulmonary function
  3. A dental evaluation and restoration
13.1 Iron overload after HCT

After a successful HCT, continuous treatment of preexisting iron overload is indicated.

After an HCT, a phlebotomy of 5 cc/kg per month should be performed until liver iron is less than 7.5 mg/g dry weight. For patients on whom phlebotomy cannot be performed, iron chelation therapy using deferoxamine is also effective, but more cumbersome and expensive than phlebotomy.

If the pre-transplantation liver biopsy was performed more than two years before starting phlebotomy, consider repeating a measurement of the LIC by noninvasive methods or by liver biopsy to confirm the baseline liver iron level. Measurement of LIC by noninvasive methods or by liver biopsy should be continued every 12 to 24 months to monitor the response to the phlebotomy. A post-HCT phlebotomy should be performed if hepatic iron before the HCT exceeds 7 mg/g dry weight, or if ferritin is greater than 2,000 ng/mL.

13.2 Experimental HCT

Since HLA-matched sibling transplantation in healthy thalassemia patients offers a very high cure rate, stem cell options for families without matched siblings are being studied. Most patients do not have an HLA-matched sibling. Experimental trials with unrelated, matched umbilical cord blood or stem cell transplantation are being conducted. Alternative immunosuppressive preparations and therapy are being studied to decrease graft-versus-host disease and improve graft survival. Pregnant mothers of affected children are more frequently undergoing prenatal diagnosis for thalassemia and determining a fetal HLA typing on the prenatal sample. If there is a match with the sibling, the umbilical cord blood cells can be stored for transplantation. An experimental procedure called pre-implantation genetic diagnosis is an option available for preselected HLA-compatible donors of affected siblings.

13.3 Experimental drug therapy to increase fetal hemoglobin

The amount of fetal hemoglobin within each red cell plays a major role in determining the severity of thalassemia. The increase in gamma globin chain synthesis decreases the alpha chain imbalance and improves the anemia. Multiple drugs have been studied to increase hemoglobin F. Histone deacetylase (HDAC) inhibitors such as butyrate and short-chain fatty acids have had benefit in select patients, but most responses have been modest and unpredictable. New HDAC drugs are under study. The first successful drug therapy for fetal hemoglobin in thalassemia was 5-azacytidine. This was abandoned because of toxicity. Recent pilot studies evaluating a safer analog (decitabine) are ongoing; however, the long-term benefit and toxicity are unknown. Erythropoietin has increased fetal hemoglobin and total hemoglobin, particularly in patients with relatively low levels of erythropoietin. However, the long-term benefit is unknown, and the risk of marrow expansion is a cause for concern.

The most successful fetal hemoglobin agent to date is oral hydroxyurea. Hydroxyurea is a cytotoxic drug that is short-acting and relatively easy to monitor. It is FDA-approved for the treatment of severe sickle cell disease. However, it is less effective and predictable in thalassemia and more likely to be beneficial in thalassemia intermedia. Approximately 40 percent of patients will have a modest increase in hemoglobin and a decrease in measurement of hemolysis. Baseline hemoglobin F is the strongest predictor of response. Splenectomy and baseline erythropoietin levels may also influence its benefit. The dosage of hydroxyurea is lower in thalassemia than in sickle cell disease. Often, the drug is started at 5 to 10 mg/kg per day and slowly escalated as tolerated to 20 mg/kg per day. While modest responses can be observed, hydroxyurea is not usually successful in preventing eventual transfusion therapy.

© 2012